about
Vitamin D and inflammatory bowel diseaseEarly post-operative endoscopic recurrence in Crohn's disease patients: data from an Italian Group for the study of inflammatory bowel disease (IG-IBD) study on a large prospective multicenter cohort.The aged gut in inflammatory bowel diseases.Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.Mucosal healing in inflammatory bowel disease: Maintain or de-escalate therapy.Disease patterns in late-onset ulcerative colitis: Results from the IG-IBD "AGED study".Lower response to the hepatitis B vaccine in future inflammatory bowel disease patients.The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar.Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study.Serology of Viral Infections and Tuberculosis Screening in an IBD Population Referred to a Tertiary Centre of Southern ItalySafety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).Pan-digestive tract colonization by cytomegalovirus in common variable immunodeficiency.Biofilm-producing fungi as emergent cause of bloodstream infections in patients with inflammatory bowel disease.Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel DiseaseA propensity score-matched comparison of infliximab and adalimumab in TNF-α inhibitors naïve and non-naïve patients with Crohn's disease: real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessmentThe real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseasesPersistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysisUnmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi ConsensusThe PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across ItalyInflammatory Bowel Disease Onset During Secukinumab Treatment: Real Concern or Just an Expression of Dysregulated Immune Response?Outcome in ulcerative colitis after switch from adalimumab/golimumab to infliximab: A multicenter retrospective study
P50
Q28085484-D1BED1C1-CB54-4EEA-BDA8-FDD4CA7D8A11Q30778152-6FA9C529-E629-4744-891F-AF9F654462A9Q35851803-739E3398-77CB-45FA-9524-AC68B551B777Q36193009-D2AA2EF9-F3D3-41D8-ADCA-4A93925A2ED0Q36578893-05600E0E-A57B-483D-B0E9-1E5803E650A2Q38813556-950148DD-3832-4798-AAA6-40AE1FC0AA1AQ38837140-AA56C7EF-2D12-4BFC-9371-9D5AAA40ADB2Q39018436-7F559F6B-0D62-4BCE-B055-4A6C620B821BQ40877160-4A2CEE48-E5AB-4E16-BE87-44C1ABD9B92FQ42718254-0BE00913-AE99-480B-8830-7C0C022A8EC2Q51152919-51FF2717-F907-4C6E-8951-6A3C0E1869B7Q51846095-A0BAF54B-7E70-4339-AC59-89DC961D13BBQ54375460-BEA9024E-094D-43A6-B557-9439D5100C00Q56959747-47F34854-8304-4BBA-B0C1-EF0F0CBF09D6Q57183563-AD49CC19-7E4A-4DC7-BDE7-C34B5ABC6C6AQ87813566-7089A76D-408B-42AE-AE12-231752FB2D71Q88167108-12184450-18C0-4E76-A291-880686BBD23CQ89523617-D1A936CB-947A-4ED6-9A83-126728CEC59CQ90211428-F2BB26D9-58D8-47BE-94AC-8040C054FF41Q90354656-5AA9844B-1BEB-4D10-A9B5-55699477C5B2Q91101175-A31CF34D-C6DD-4050-BC0D-FB5CEB1DE8EEQ92552682-C36CA73D-C5BF-43C8-ACC4-9097B1700FA7Q93345804-F9732DCA-CE19-435A-8E38-01EF06CEAC8B
P50
description
researcher
@en
wetenschapper
@nl
name
Walter Fries
@en
Walter Fries
@nl
type
label
Walter Fries
@en
Walter Fries
@nl
prefLabel
Walter Fries
@en
Walter Fries
@nl
P106
P31
P496
0000-0001-6159-7478